Foundation Partners
UOM Logo Doherty Logo Burnet Logo
Major Supporting Partner
VIC Logo

AIID Facility

A new high-tech research facility for Australia

A new centre for infectious diseases research, education and public health will be built in Melbourne to house the Australian Institute for Infectious Disease (AIID). State-of-the-art research platforms and technology will enable the development of faster, more effective diagnostic tests, treatments, vaccines, and public health interventions for infectious diseases.

The new facility will be built in the Melbourne Biomedical Precinct, connecting to the existing Doherty Institute building on Elizabeth Street. It will enable the University of Melbourne and Doherty Institute to expand and the Burnet Institute to relocate to the Parkville site.

The AIID facility is scheduled for completion in 2029 with commissioning and operations to follow.

Learn more about the AIID facility from our leaders in this video:

 

Facility progress to date

With government funding secured, a strong business case finalised and site demolition commenced, the AIID project is well underway.  

Leading Melbourne architectural firm, Wardle is the lead architectural firm and Aurecon is the lead engineering firm. 

Concept design for the building was completed in early 2023, and schematic design completed in early 2024 with input and collaboration from Foundation Partner researchers and staff, who will ultimately be the future users of the building’s cutting-edge facilities. 

Kane Constructions has been engaged for the early and enabling works which commenced in early 2024, and key planning approvals for the building design and construction were achieved in mid-2025 as explained in the below video.

Images of the building design can be seen below:

 

Facilities and research platforms

The AIID will provide vital facilities and research platforms needed to develop vaccines and treatments for infectious diseases, including:

  • New high containment facilities enabling identification, isolation and characterisation of new viruses and other infectious diseases.
  • New drug screening, imaging and testing in high containment needed for early-stage human drug and vaccine research.
  • Human infection challenge unit designed to accelerate the development of new medicines and vaccines for key partners and industry clients, through high-quality and ethical clinical research.
  • Robotic biobanking to store biomedical samples efficiently and safely from large clinical trials.
  • Public health genomics, incorporating future technologies and Artificial Intelligence (AI) to allow for rapid outbreak response and understand transmission of infectious diseases.
  • Cross-disciplinary disease transmission modelling for prediction of new outbreaks and intervention impact.
  • Dedicated industry partner space for production and commercialisation of medical products and procedures to improve health outcomes.